#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14804	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2125	691.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1693	1693	T	811	T,C	746,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14804	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2125	691.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1427	1427	C	885	C,T	815,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26878	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3529	756.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1635	1635	A	855	A,G	804,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26878	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3529	756.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2269	2269	C	830	C	765	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26878	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3529	756.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2343	2343	A	859	A	807	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26878	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3529	756.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2895	2895	C	785	C	734	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	27	1886	folP	852	852	99.88	folP.l15.c4.ctg.1	1519	123.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3344	146.6	1	SNP	p	S91F	0	.	.	271	273	TCC	548	550	TCC	174;178;180	T;C;C	160;162;163	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3344	146.6	1	SNP	p	D95N	0	.	.	283	285	GAC	560	562	GAC	168;167;168	G;A;C	154;153;155	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4932	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3344	146.6	1	SNP	p	D95G	0	.	.	283	285	GAC	560	562	GAC	168;167;168	G;A;C	154;153;155	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	539	1558	mtrR	633	633	99.37	mtrR.l6.c17.ctg.1	1199	128.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	440	442	ACC	176;173;171	A,G;C;C	159,1;164;162	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	844	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	935	88.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1456	1458	ATC	178;180;180	A;T;C	164;167;167	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1609	1611	GCA	185;188;189	G,A;C,T;A,G	172,1;167,2;168,2	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2092	2094	ATT	202;204;205	A;T;T	184;184;186	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	1	SNP	p	D86N	0	.	.	256	258	GAC	562	564	GAC	186;187;188	G;A;C	171;171;176	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	1	SNP	p	S87I	0	.	.	259	261	AGT	565	567	AGT	185;187;187	A,C;G;T	170,1;174;173	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	1	SNP	p	S87W	0	.	.	259	261	AGT	565	567	AGT	185;187;187	A,C;G;T	170,1;174;173	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	1	SNP	p	S87R	0	.	.	259	261	AGT	565	567	AGT	185;187;187	A,C;G;T	170,1;174;173	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4618	parC	2304	2304	99.7	parC.l15.c30.ctg.1	2923	156.8	1	SNP	p	S88P	0	.	.	262	264	TCC	568	570	TCC	184;186;186	T,C;C;C	170,1;176;175	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4244	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2582	163.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1551	1553	GGC	264;260;258	G;G;C	238;235;232	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1203	1205	GCA	217;218;219	G;C;A	200;202;204	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1206	1208	ATC	222;224;227	A;T;C,T	204;207;209,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1218	1220	GTG	242;241;242	G;T;G	221;220;222	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1218	1220	GTG	242;241;242	G;T;G	221;220;222	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1722	1724	ACC	214;214;214	A;C;C	191;200;199	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1776	1778	GCG	229;227;229	G;C;G	205;180;196	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1776	1778	GCG	229;227;229	G;C;G	205;180;196	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1899	1901	GGT	209;208;210	G;G;T	190;188;191	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1908	1910	GGC	199;200;198	G;G;C	181;182;180	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4114	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2458	166.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1926	1928	CCG	187;188;187	C;C,A;G	144;161,1;150	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5710	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2845	198.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1946	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1816	106.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	576	576	C	154	C	138	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	81	83	AAT	13;13;13	A;A;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	84	86	AAT	13;13;13	A;A;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	A222V	NONSYN	664	666	GCT	96	98	GTT	13;13;13	G;T,C;T,C	13;12,1;12,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	108	110	GCG	12;12;11	G;C;G,A	11;12;10,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	131	133	GTA	10;9;9	G;T;A	10;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	N237K	NONSYN	709	711	AAC	140	142	AAA	6;6;6	A;A;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	242	porB1a	984	188	90.1	porB1a.l15.c17.ctg.2	251	20.7	0	.	p	.	0	D238fs	FSHIFT	712	712	G	143	143	G	12	G	11	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	782	784	CAA	223;222;228	C;A;A	208;206;213	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	E212G	NONSYN	634	636	GAA	989	991	GGT	262;262;262	G;G;T	245;248;243	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	H213G	NONSYN	637	639	CAT	992	994	GGT	262;264;265	G;G;T	248;249;243	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	V215A	NONSYN	643	645	GTT	998	1000	GCT	264;261;258	G;C;T	251;247;245	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1007	1009	ATG	253;252;251	A;T;G,A	242;241;239,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1124	1126	AAG	243;244;247	A;A;G	225;228;231	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	D294N	NONSYN	880	882	GAT	1235	1237	AAT	244;244;245	A,G,C;A;T	229,1,1;232;231	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	0	.	p	.	0	D333N	NONSYN	997	999	GAC	1352	1354	AAC	204;207;207	A,G;A;C	189,1;191;192	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2834	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1765	159.9	1	SNP	p	G120K	0	.	.	358	360	GGC	713	715	GGC	203;201;203	G;G;C	195;194;195	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11296	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	4826	232.8	0	.	p	.	0	V1359I	NONSYN	4075	4077	GTC	4370	4372	ATC	264;262;266	A,G;T,A;C	244,1;242,1;247	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11296	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	4826	232.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1952	1954	CAT	257;259;257	C;A;T	238;241;239	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1264	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	949	131.8	1	SNP	p	V57M	0	.	.	169	171	GTG	499	501	GTG	268;269;267	G;T;G	251;247;250	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
